Literature DB >> 9083092

Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA.

B W Carpick1, V Graziano, D Schneider, R K Maitra, X Lee, B R Williams.   

Abstract

The antiviral activity of the interferon-induced, double-stranded RNA (dsRNA)-activated protein kinase (PKR) is mediated through dsRNA binding leading to PKR autophosphorylation and subsequent inhibition of protein synthesis. Previous biochemical studies have suggested that autophosphorylation of PKR occurs via a protein-protein interaction and that PKR can form dimers in vitro. Using four independent biophysical and biochemical methods, we have characterized the solution complex formed between PKR and trans-activating region (TAR) RNA, a 57-nucleotide RNA species with double-stranded secondary structure derived from the human immunodeficiency virus type I genome. Chemical cross-linking and gel filtration analyses of PKR.TAR RNA complexes reveals that TAR RNA addition increases PKR dimerization and results in the formation of a solution complex with a molecular weight of approximately 150,000. Addition of TAR RNA to PKR results in a quenching of tryptophan fluorescence, indicative of a conformational shift. Through small angle neutron scattering analysis, we show that PKR exists in solution predominantly as a dimer, and has an elongated solution structure. Addition of TAR RNA to PKR causes a significant conformational shift in the protein at a 2:1 stoichiometric ratio of protein to RNA. Taken together, these data indicate that the PKR activation complex consists of a protein dimer bound cooperatively to one dsRNA molecule.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083092     DOI: 10.1074/jbc.272.14.9510

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Modular structure of PACT: distinct domains for binding and activating PKR.

Authors:  G A Peters; R Hartmann; J Qin; G C Sen
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR.

Authors:  S Nanduri; F Rahman; B R Williams; J Qin
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

4.  Heterologous dimerization domains functionally substitute for the double-stranded RNA binding domains of the kinase PKR.

Authors:  T L Ung; C Cao; J Lu; K Ozato; T E Dever
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

5.  The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR).

Authors:  Xu Huang; Brian Hutchins; Rekha C Patel
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

6.  Analysis of PKR activation using analytical ultracentrifugation.

Authors:  James L Cole
Journal:  Macromol Biosci       Date:  2010-07-07       Impact factor: 4.979

7.  Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein.

Authors:  Gregory A Peters; David Khoo; Ian Mohr; Ganes C Sen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR.

Authors:  O Donzé; T Abbas-Terki; D Picard
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

9.  Analysis of PKR structure by small-angle scattering.

Authors:  Jennifer VanOudenhove; Eric Anderson; Susan Krueger; James L Cole
Journal:  J Mol Biol       Date:  2009-02-14       Impact factor: 5.469

10.  Evidence for auto-inhibition by the N terminus of hADAR2 and activation by dsRNA binding.

Authors:  Mark R Macbeth; Arunth T Lingam; Brenda L Bass
Journal:  RNA       Date:  2004-10       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.